← Leaderboards
Russell P Tracy
University Of Vermont &St Agric College
$21,451,891
Attributed
$62,738,824
Total exposure
21
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$62,738,824 · 21
By mechanism
U24$27,648,731 · 1
R01$20,953,637 · 9
U01$6,623,044 · 1
UH3$3,045,497 · 1
UH2$2,038,893 · 1
N01$757,522 · 2
Top collaborators
- Bruce M Psaty16 shared
- Michael E. Miller12 shared
- Walter John Rejeski12 shared
- Marco Pahor8 shared
- Steven R Cummings7 shared
- Karyn Ann Esser6 shared
- Peter Ganz6 shared
- Jorge R Kizer6 shared
Most similar at University Of Vermont &St Agric College
Same institution · by research overlap
- Kenneth G Mann$16,215,469
- Michael E. Nesheim$1,529,492
- Paula B Tracy$4,267,067
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortParticipantFutureSamplingAtherosclerosisAgingBiological MarkersRisk FactorsInnovationCardiovascular HealthBaseResearch PersonnelScienceCoronary Heart DiseaseCardiovascular DiseasesBiologyPublic Health RelevanceInflammationStrokeCohort StudiesEventHeart FailurePlayReporting
Grant awards (67)
Molecular Transducers of Physical Activity Consortium Coordinating Center$1,200,000
U24 · FY2025 · AR
Molecular Transducers of Physical Activity Consortium Coordinating Center$2,800,000
U24 · FY2024 · AR
MoTrPAC CCC Supplement$200,269
U24 · FY2024 · AR
Molecular Transducers of Physical Activity Consortium Coordinating Center$3,100,000
U24 · FY2023 · AR
MoTrPAC Supplemental Funding for Miller$65,129
U24 · FY2023 · AR
MoTrPAC Consortium Coordinating Center$1
U24 · FY2022 · AR
MoTrPAC Consortium Coordinating Center$2,927,717
U24 · FY2021 · AR
Plasma proteomics in CHS and population biology$1,076,097
R01 · FY2021 · HL
Innate and adaptive immune-cell densities as risk factors for heart failure$677,311
R01 · FY2021 · HL
MoTrPAC Consortium Coordinating Center$2,671,620
U24 · FY2020 · AR
Plasma proteomics in CHS and population biology$2,083,439
R01 · FY2020 · HL
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$974,558
UH3 · FY2020 · NS
Innate and adaptive immune-cell densities as risk factors for heart failure$685,835
R01 · FY2020 · HL
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2020 · AG
MoTrPAC Consortium Coordinating Center$8,248,259
U24 · FY2019 · AR
Plasma proteomics in CHS and population biology$1,799,932
R01 · FY2019 · HL
CHS research resources for the cardiovascular health of older adults$1,552,443
U01 · FY2019 · HL
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$989,999
UH3 · FY2019 · NS
Innate and adaptive immune-cell densities as risk factors for heart failure$736,213
R01 · FY2019 · HL
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2019 · AG
MoTrPAC Consortium Coordinating Center$5,614,654
U24 · FY2018 · AR
CHS research resources for the cardiovascular health of older adults$1,538,449
U01 · FY2018 · HL
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$1,080,940
UH3 · FY2018 · NS
Innate and adaptive immune-cell densities as risk factors for heart failure$741,580
R01 · FY2018 · HL
Phenotypes of Aging & Senescence$683,773
R56 · FY2018 · AG
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2018 · AG
CHS research resources for the cardiovascular health of older adults$397,655
U01 · FY2018 · HL
CHS research resources for the cardiovascular health of older adults$1,556,769
U01 · FY2017 · HL
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$1,001,222
UH2 · FY2017 · NS
Immune function and the risk of cvd among HIV infected and uninfected veterans$691,563
R01 · FY2017 · HL
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2017 · AG
MoTrPAC Consortium Coordinating Center$571,082
U24 · FY2017 · AR
T-cell subsets as CVD risk factors in CHS and MESA$550,131
R01 · FY2017 · HL
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$433,273
R01 · FY2017 · HL
MoTrPAC Consortium Coordinating Center$250,000
U24 · FY2017 · AR
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins - SUPPLEMENT$4,925
R01 · FY2017 · AG
CHS research resources for the cardiovascular health of older adults$1,577,728
U01 · FY2016 · HL
Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium$1,037,671
UH2 · FY2016 · NS
Immune function and the risk of cvd among HIV infected and uninfected veterans$697,207
R01 · FY2016 · HL
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$667,919
R01 · FY2016 · HL
T-cell subsets as CVD risk factors in CHS and MESA$635,172
R01 · FY2016 · HL
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins$635,000
R01 · FY2016 · AG
IGF::OT::IGF - University of Vermont to provide support services for the CHS Biospecimen Repository for a period of performance of one (1) year.$98,569
N02 · FY2016 · HL · contact PI
IGF::OT::IGF - University of Vermont to provide support services for the NHLBI Urine Sodium Substudy - Transfer of Samples for a period of performance of one (1) year.$80,290
N02 · FY2016 · HL · contact PI
T-cell subsets as CVD risk factors in CHS and MESA$707,950
R01 · FY2015 · HL
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$554,349
R01 · FY2015 · HL
Immune function and the risk of cvd among HIV infected and uninfected veterans$416,338
R01 · FY2015 · HL
Immune function and the risk of cvd among HIV infected and uninfected veterans$289,192
R01 · FY2015 · HL
Immune function and the risk of cvd among HIV infected and uninfected veterans$754,326
R01 · FY2014 · HL
T-cell subsets as CVD risk factors in CHS and MESA$726,570
R01 · FY2014 · HL
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$638,645
R01 · FY2014 · HL
Epidemiology of Vascular Inflammation & Atherosclerosis$340,250
R01 · FY2007 · HL · contact PI
Epidemiology of Vascular Inflammation & Atherosclerosis$350,412
R01 · FY2006 · HL · contact PI
Epidemiology of Vascular Inflammation &Atherosclerosis$358,845
R01 · FY2005 · HL
AGING-DEPENDENT CHANGES - PILOT STUDY$20,330
M01 · FY2005 · RR
GIVEN BUILDING ANIMAL FACILITY UPGRADE$520,555
G20 · FY2004 · RR
Epidemiology of Vascular Inflammation &Atherosclerosis$371,845
R01 · FY2004 · HL
Aging-dependent Changes - Pilot Study$13,997
M01 · FY2004 · RR
INFLAMMATION MARKERS OVER TIME IN CARDIOVASCULAR DISEASE$168,704
R01 · FY2002 · HL
INFLAMMATION MARKERS OVER TIME IN CARDIOVASCULAR DISEASE$216,586
R01 · FY2001 · HL
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY$0
N01 · FY2001 · HC
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY$454,444
N01 · FY2000 · HC
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY$303,078
N01 · FY2000 · HC
CORE--CELL BIOLOGY$253,986
P01 · FY2000 · HL
INFLAMMATION MARKERS OVER TIME IN CARDIOVASCULAR DISEASE$209,550
R01 · FY2000 · HL
EPIDEMIOLOGY OF IMPAIRED COAGULANT BALANCE IN DIABETES$194,478
R01 · FY2000 · HL
CENTRAL BLOOD ANALYSIS LABORATORY FOR CHS$0
N01 · FY2000 · HC